Pfizer (NYSE:PFE) Releases FY 2025 Earnings Guidance

Pfizer (NYSE:PFE) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.000-3.150 for the period, compared to the consensus estimate of 3.150. The company issued revenue guidance of $62.0 billion-$62.0 billion, compared to the consensus revenue estimate of $62.6 billion.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Bank of America cut their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, HSBC reiterated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Stock Up 0.7%

Shares of PFE opened at $25.05 on Thursday. The firm has a 50 day simple moving average of $25.13 and a two-hundred day simple moving average of $24.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer has a one year low of $20.92 and a one year high of $27.69. The company has a market cap of $142.40 billion, a P/E ratio of 14.56 and a beta of 0.46.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks highlights Pfizer’s strengthened oncology and obesity pipeline as potential drivers of post‑loss‑of‑exclusivity growth, which supports longer‑term revenue upside beyond 2026–2030 LOEs. PFE’s Oncology & Obesity Pipeline Position It for Post-LOE Growth
• Positive Sentiment: Reports that Pfizer is advancing biopharmaceutical operations globally point to improved manufacturing and commercial readiness, which can reduce execution risk for upcoming launches and support margins. Pfizer Inc (NYSE:PFE) Advances Biopharmaceutical Operations Globally
• Neutral Sentiment: Pfizer announced completion milestones in a pediatric Protonix (Phase 2) study — an incremental clinical update investors should watch for data readouts or regulatory next steps, but the item has limited immediate revenue impact until results are reported. Pfizer’s Protonix Pediatric Study Completion: What Investors Should Watch Next
• Negative Sentiment: Pfizer disclosed a patient death in a long‑term hemophilia study (linked to its Hympavzi/marstacimab program), prompting a safety review and reassessment of surgical protocols—this raises potential safety, regulatory and labeling risk that weighs on near‑term sentiment. Pfizer says patient dies after receiving hemophilia drug in trial
• Negative Sentiment: Management set FY‑2025 EPS guidance of $3.00–$3.15 and revenue guidance around $62.0B, both slightly below consensus — a near‑term earnings/revenue miss that increases uncertainty around 2025 results and likely contributed to selling pressure. (Market commentary tying the guidance cut and trial death to a tightened risk/reward is discussed here.) Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer’s (PFE) Risk–Reward Story?

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of the stock. State Street Corp grew its stake in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after acquiring an additional 2,786,098 shares in the last quarter. Northern Trust Corp grew its stake in shares of Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after acquiring an additional 869,175 shares during the period. Amundi increased its stake in shares of Pfizer by 10.8% in the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after purchasing an additional 4,043,413 shares in the last quarter. Invesco Ltd. grew its stake in Pfizer by 3.7% in the 3rd quarter. Invesco Ltd. now owns 30,335,842 shares of the biopharmaceutical company’s stock valued at $772,957,000 after buying an additional 1,085,701 shares in the last quarter. Finally, Unisphere Establishment raised its holdings in Pfizer by 13.8% during the 3rd quarter. Unisphere Establishment now owns 14,400,000 shares of the biopharmaceutical company’s stock valued at $366,912,000 after acquiring an additional 1,750,000 shares during the period. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.